Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis
- PMID: 12737866
- DOI: 10.1016/s0140-6736(03)13171-6
Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis
Abstract
An increase in invasive Hib disease incidence in the UK has coincided with the distribution of combination vaccines that contain acellular pertussis (DTaP-Hib). These vaccines have been associated with reduced immunogenicity of the Hib component, although there is little agreement on the clinical relevance of this finding. We retrospectively compared vaccine formulations given to fully vaccinated Hib cases with those administered to fully immunised age-matched controls using conditional logistic regression. More cases than controls received all three doses of their infant primary course as DTaP-Hib, compared with two or three doses of another Hib vaccine (conditional odds ratio 6.77 [95% CI 3.26-14.07]).
Comment in
-
Why the rise in Haemophilus influenzae type b infections?Lancet. 2003 Jul 26;362(9380):330-1. doi: 10.1016/S0140-6736(03)13985-2. Lancet. 2003. PMID: 12892973 No abstract available.
-
Why the rise in Haemophilus influenzae type b infections?Lancet. 2003 Jul 26;362(9380):331. doi: 10.1016/S0140-6736(03)13986-4. Lancet. 2003. PMID: 12892974 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
